Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.
Tirzepatide is a first-in-class, once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Given the tight link between hyperglycemia, adiposity, and cardiovascular disease, tirzepatide has rapidly gained interest as a broader cardiometabolic intervention. This narrat...
| Publicado en: | Clinical Medicine Insights: Cardiology Vol. 20; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
6/16/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194639464&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194639464 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795468 B3KL jtl: Clinical Medicine Insights: Cardiology issn: 11795468 maglogo: Y pubinfo: dt: 6/16/2026 vid: 20 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 194639464 194639464 194639464 10.1177/11795468261460202 194639464 ppf: 1 ppct: 10 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence. aug: au: Parlati, Antonio LM Martini, Luca Nardi, Ermanno Carluccio, Raffaele Parlati, Luca EP Madaudo, Cristina Perrone Filardi, Pasquale affil: Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy sug: subj: Diabetes Mellitus, Type 2 Drug Therapy Obesity Drug Therapy Glucagon-Like Peptide-1 Receptor Agonists Therapeutic Use Drug Evaluation Cardiovascular Risk Factors Risk Assessment Heart Failure Risk Factors Glycated Hemoglobin Drug Effects Weight Loss Drug Effects Waist Circumference Blood Pressure Triglycerides Biological Markers Inflammation Hyperlipidemia Hypertension Sleep Apnea, Obstructive Drug Tolerance Patient Safety ab: Tirzepatide is a first-in-class, once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Given the tight link between hyperglycemia, adiposity, and cardiovascular disease, tirzepatide has rapidly gained interest as a broader cardiometabolic intervention. This narrative review summarizes mechanistic rationale and clinical evidence on cardiovascular risk-factor modification, cardiorenal signals, and outcome data. Across the SURPASS program in type 2 diabetes, tirzepatide produces large, dose-dependent reductions in HbA1c and substantial weight loss, with consistent benefits versus active comparators. In obesity, the SURMOUNT trials showed marked and durable weight reduction over long follow-up, with clinically relevant improvements in waist circumference, blood pressure, triglycerides, and inflammatory biomarkers. Beyond weight and glycaemia, available data suggest favorable effects on lipids, ambulatory blood pressure, inflammatory markers, and kidney-related endpoints in exploratory analyses. Tirzepatide also improves obstructive sleep apnea severity in adults with obesity. Regarding cardiovascular outcomes, SURPASS-CVOT supports cardiovascular safety by demonstrating noninferiority versus dulaglutide for 3-point major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). In obesity-related HFpEF, SUMMIT shows reductions in worsening heart failure (HF) events and improvements in health status, supporting a phenotype-specific role in HF. Overall, tirzepatide is emerging as a key therapeutic option for integrated cardiometabolic risk reduction, with ongoing research needed to define its incremental benefit versus established GLP-1 receptor agonists, long-term effectiveness in routine care, and optimal positioning across HF phenotypes. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|